Sections

Commentary

Amphetamines, Atomoxetine and the Risk of Serious Cardiovascular Events in Adults

Hedi Schelleman,
HS
Hedi Schelleman
Warren B. Bilker,
WBB
Warren B. Bilker
Stephen E. Kimmel,
SEK
Stephen E. Kimmel
Gregory W. Daniel,
GWD
Gregory W. Daniel Former Brookings Expert, HealthCore
Craig Newcomb,
CN
Craig Newcomb
James P. Guevara,
JPG
James P. Guevara
Mark J. Cziraky,
MJC
Mark J. Cziraky
Brian L. Strom, and
BLS
Brian L. Strom
Sean Hennessy
SH
Sean Hennessy

January 31, 2013

Main Objective

To compare the incidence rates of serious cardiovascular events in adult initiators of amphetamines or atomoxetine to rates in non-users.

Methods 

This was a retrospective cohort study of new amphetamines (n = 38,586) or atomoxetine (n = 20,995) users. Each medication user was matched to up to four non-users on age, gender, data source, and state (n = 238,183). The following events were primary outcomes of interest 1) sudden death or ventricular arrhythmia, 2) stroke, 3) myocardial infarction, 4) a composite endpoint of stroke or myocardial infarction. Cox proportional hazard regression was used to calculate propensity-adjusted hazard ratios for amphetamines versus matched non-users and atomoxetine versus matched non-users, with intracluster dependence within matched sets accounted for using a robust sandwich estimator.

Results 

The propensity-score adjusted hazard ratio for amphetamines use versus non-use was 1.18 (95% CI: 0.55–2.54) for sudden death/ventricular arrhythmia, 0.80 (95% CI: 0.44–1.47) for stroke, 0.75 (95% CI: 0.42–1.35) for myocardial infarction, and 0.78 (95% CI: 0.51–1.19) for stroke/myocardial infarction. The propensity-score adjusted hazard ratio for atomoxetine use versus non-use was 0.41 (95% CI: 0.10–1.75) for sudden death/ventricular arrhythmia, 1.30 (95% CI: 0.52–3.29) for stroke, 0.56 (95% CI: 0.16–2.00) for myocardial infarction, and 0.92 (95% CI: 0.44–1.92) for stroke/myocardial infarction.

Conclusions 

Initiation of amphetamines or atomoxetine was not associated with an elevated risk of serious cardiovascular events. However, some of the confidence intervals do not exclude modest elevated risks, e.g. for sudden death/ventricular arrhythmia.

Read the article at plosone.org »

The Brookings Institution is committed to quality, independence, and impact.
We are supported by a diverse array of funders. In line with our values and policies, each Brookings publication represents the sole views of its author(s).